Molecular glue therapeutic - AnHorn Medicines
Latest Information Update: 28 Aug 2023
At a glance
- Originator AnHorn Medicines
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 21 Jul 2023 Early research in Non-Hodgkin's lymphoma in Taiwan (Parenteral) prior to July 2023 (AnHorn Medicines pipeline, July 2023)